中国寄生虫学与寄生虫病杂志 ›› 2018, Vol. 36 ›› Issue (5): 435-442.
刘琴, 陈木新, 李元元, 张仪, 李石柱, 陈家旭, 周晓农*()
收稿日期:
2018-06-08
出版日期:
2018-10-30
发布日期:
2018-11-13
通讯作者:
周晓农
基金资助:
Qin LIU, Mu-xin CHEN, Yuan-yuan LI, Yi ZHANG, Shi-zhu LI, Jia-xu CHEN, Xiao-nong ZHOU*()
Received:
2018-06-08
Online:
2018-10-30
Published:
2018-11-13
Contact:
Xiao-nong ZHOU
Supported by:
摘要:
人类非洲锥虫病(human African trypanosomiasis,HAT)是一种被忽视的热带病,其诊断和治疗均较复杂。近年来,世界经济发展和人员流动频繁,输入性的HAT病例也逐渐增加。因此,对专业技术人员相关知识和技术的培训显得尤为重要。本文系统地整理了HAT的诊断技术和治疗方案,以供临床医师和疾病预防控制机构技术人员参考。
中图分类号:
刘琴, 陈木新, 李元元, 张仪, 李石柱, 陈家旭, 周晓农. 非洲锥虫病的诊断和治疗[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(5): 435-442.
Qin LIU, Mu-xin CHEN, Yuan-yuan LI, Yi ZHANG, Shi-zhu LI, Jia-xu CHEN, Xiao-nong ZHOU. Diagnosis and treatment of human African trypanosomiasis[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2018, 36(5): 435-442.
表1
g-HAT与r-HAT的比较
类型 | g-HAT | r-HAT |
---|---|---|
病原体 | 布氏锥虫冈比亚亚种 | 布氏锥虫罗德西亚种 |
分布 | 非洲中部和西部 | 非洲东部和南部 |
急性或慢性 | 通常为慢性 | 通常为急性 |
病例比例 | 95%以上的病例 | 5%以下的病例 |
主要传播媒介的种类 | 主要是Nemorhina 亚属的采采蝇 | 主要是Glossina亚属的采采蝇 |
保藏宿主 | 主要是人类 | 人畜共患病,多种野生动物及家畜均为保藏宿主 |
虫血症水平 | 很低(通常<100个 锥虫/ml血) | 相对较高,病原学检测较易 |
病程 | 进入第二阶段平均 需要300~500 d | 进入第二阶段平均需要3周~2个月 |
第一阶段一线治疗药物 | 戊烷脒 | 苏拉明 |
第二阶段一线治疗药物 | 硝夫替莫和依氟鸟氨酸 联合用药(NECT) | 美拉胂醇 |
是否有血清学检测 | 有 | 否 |
分子检测特异性基因 | 特异性的单拷贝布氏锥虫冈比亚亚种的可变抗原(TgSGP)基因 | 特异性的单拷贝的血清抗性相关(SRA)基因 |
表3
WHO推荐HAT不同阶段的治疗药物
g-HAT | r-HAT | ||||||||
---|---|---|---|---|---|---|---|---|---|
阶段 | 第一线治疗药物 | 备选治疗药物 | 第一线治疗药物 | 备选治疗药物 | |||||
药物名称 | 给药方案 | 药物名称 | 给药方案 | 药物名称 | 给药方案 | 药物名称 | 给药方案 | ||
第一阶段 | 戊烷脒 | 4 mg/(kg·d)肌内注射或是稀释于生理盐水在2 h内静脉注射,连续7 d | 苏拉明 | 第1天4~5 mg/kg静脉注射(实验性给药),然后20 mg/kg静脉注射,每周1次,连续5周(每次最大剂量不超过1 g,时间分别为第3、10、17、24和31天) | 戊烷脒(在没有苏拉明的情况下使用,可延缓病情发展) | 4 mg/(kg·d)肌内注射或是稀释于生理盐水在2 h内静注,连续7 d | |||
第二阶段 | 硝夫替莫和依氟鸟氨酸联合用药(NECT) | 硝夫替莫15 mg/(kg·d)分3次口服,连续10 d;依氟鸟氨酸400 mg/(kg·d),分两次静脉注射,每次溶于250 ml生理盐水,在2 h内注射完,连续7 da | 依氟鸟氨酸(第二线药物);美拉胂醇(第三线药物,只在复发时使用) | 依氟鸟氨酸,剂量400 mg/(kg·d),分4次静脉注射,每次溶于100 ml生理盐水,在2 h注射完,连续14 d;美拉胂醇静脉注射,剂量2.2 mg/(kg·d),连续10 d | 美拉胂醇 | 2.2 mg/(kg·d),静脉注射,连续10 d |
[1] | Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee[J]. World Health Organ Tech Rep Ser, 2013, 881: Ⅰ-Ⅵ, 1-114. |
[2] | 甘绍伯. 非洲锥虫病[J]. 中国热带医学, 2009, 9(6): 983-984. |
[3] | Franco JR, Simarro PP, Diarra A, et al. Epidemiology of human African trypanosomiasis[J]. Clin Epidemiol, 2014, 6: 257-275. |
[4] | Büscher P, Cecchi G, Jamonneau V, et al. Human African trypanosomiasis[J]. Lancet, 2017, 390(10110): 2397-2409. |
[5] | Franco JR, Cecchi G, Priotto G, et al. Monitoring the elimination of human African trypanosomiasis: Update to 2014[J]. PLoS Negl Trop Dis, 2017, 11(5): e0005585. |
[6] | Simarro PP, Franco JR, Cecchi G, et al. Human African trypanosomiasis in non-endemic countries(2000-2010)[J]. J Travel Med, 2012, 19(1): 44-53. |
[7] | Wang X, Ruan Q, Xu B, et al. Human African trypanosomiasis in emigrant returning to China from Gabon, 2017[J]. Emerging Infect Dis, 2018, 24(2): 400-404. |
[8] | Chappuis F, Pittet A, Bovier PA, et al. Field evaluation of the CATT/Trypanosoma brucei gambiense on blood-impregnated filter papers for diagnosis of human African trypanosomiasis in southern Sudan[J]. Trop Med Int Health, 2002, 7(11): 942-948. |
[9] | Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study[J]. Lancet Glob Health, 2014, 2(6): e359-e363. |
[10] | Lumbala C, Bessell PR, Lutumba P, et al. Performance of the SD BIOLINE® HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo[J]. PLoS One, 2017, 12(7): e0180555. |
[11] | Bisser S, Lumbala C, Nguertoum E, et al. Sensitivity and specificity of a prototype rapid diagnostic test for the detection of Trypanosoma brucei gambiense infection: a multi-centric prospective study[J]. PLoS Negl Trop Dis, 2016, 10(4): e0004608. |
[12] | Camara O, Camara M, Lejon V, et al. Immune trypanolysis test with blood spotted on filter paper for epidemiological surveillance of sleeping sickness[J]. Trop Med Int Health, 2014, 19(7): 828-831. |
[13] | Kagbadouno MS, Camara M, Rouamba J, et al. Epidemiology of sleeping sickness in Boffa (Guinea): where are the trypanosomes[J]. PLoS Negl Trop Dis, 2012, 6(12): e1949. |
[14] | Reijer PJ, Beckers EJ.Rhodesiense trypanosomiasis, complicated by ascites. A case report[J]. Trop Geogr Med, 1982, 34(3): 274-276. |
[15] | Pyana PP, Ngay Lukusa I, Mumba Ngoyi D, et al. Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice[J]. PLoS Negl Trop Dis, 2011, 5(4): e1025. |
[16] | Mumba Ngoyi D, Menten J, Pyana PP, et al. Stage determination in sleeping sickness: comparison of two cell counting and two parasite detection techniques[J]. Trop Med Int Health, 2013, 18(6): 778-782. |
[17] | Camara M, Camara O, Ilboudo H, et al. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test[J]. Trop Med Int Health, 2010, 15(7): 796-799. |
[18] | Büscher P, Mumba Ngoyi D, Kaboré J, et al. Improved models of mini anion exchange centrifugation technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness diagnosis and staging[J]. PLoS Negl Trop Dis, 2009, 3(11): e471. |
[19] | Miézan TW, Meda HA, Doua F, et al. Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes[J]. Trans R Soc Trop Med Hyg, 2000, 94(3): 293. |
[20] | Büscher P, Deborggraeve S.How can molecular diagnostics contribute to the elimination of human African trypanosomiasis[J]. Expert Rev Mol Diagn, 2015, 15(5): 607-615. |
[21] | Deborggraeve S, Lejon V, Ekangu RA, et al. Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study[J]. PLoS Negl Trop Dis, 2011, 5(2): e972. |
[22] | Kirchhoff LV.Use of a PCR assay for diagnosing African trypanosomiasis of the CNS: a case report[J]. Cent Afr J Med, 1998, 44(5): 134-136. |
[23] | Deborggraeve S, Büscher P.Molecular diagnostics for sleeping sickness: what is the benefit for the patient[J]. Lancet Infect Dis, 2010, 10(6): 433-439. |
[24] | 孙懿, 黄韦华, 牛紫光, 等. 1例输入性非洲锥虫病的病原学鉴定[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(4): 350-354. |
[25] | Gibson W, Backhouse T, Griffiths A.The human serum resistance associated gene is ubiquitous and conserved in Trypanosoma brucei rhodesiense throughout East Africa[J]. Infect Genet Evol, 2002, 1(3): 207-214. |
[26] | Campillo N, Carrington M.The origin of the serum resistance associated (SRA) gene and a model of the structure of the SRA polypeptide from Trypanosoma brucei rhodesiense[J]. Mol Biochem Parasitol, 2003, 127(1): 79-84. |
[27] | Radwanska M, Magnus E, Claes F, et al. Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense[J]. Am J Tropl Med Hyg, 2002, 67(3): 289-295. |
[28] | Bonnet J, Boudot C, Courtioux B.Overview of the diagnostic methods used in the field for human African trypanosomiasis: what could change in the next years?[J]. BioMed Res Int, 2015, 2015: 583262. |
[29] | 万学红, 卢雪峰. 诊断学[M]. 北京: 人民卫生出版社, 2013: 327. |
[30] | Barrett MP, Vincent IM, Burchmore RJ, et al. Drug resistance in human African trypanosomiasis[J]. Future Microbiol, 2011, 6(9): 1037-1047. |
[31] | Tiberti N, Matovu E, Hainard A, et al. New biomarkers for stage determination in Trypanosoma brucei rhodesiense sleeping sickness patients[J]. Clin Transl Med, 2013, 2(1): 1. |
[32] | Amin DN, Ngoyi DM, Nhkwachi GM, et al. Identification of stage biomarkers for human African trypanosomiasis[J]. Am J Trop Med Hyg, 2010, 82(6): 983-990. |
[33] | Njamnshi AK, Gettinby G, Kennedy PGE.The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question[J]. Trans R Soc Trop Med Hyg, 2017, 111(5): 199-203. |
[34] | Pohlig G, Bernhard SC, Blum J, et al. Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international phase 3 clinical trial[J]. PLoS Negl Trop Dis, 2016, 10(2): e0004363. |
[35] | Babokhov P, Sanyaolu AO, Oyibo WA, et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis[J]. Pathog Glob Health, 2013, 107(5): 242-252. |
[36] | Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase Ⅲ, non-inferiority trial[J]. Lancet, 2009, 374(9683): 56-64. |
[37] | Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis[J]. Cochrane Database Syst Rev, 2013(6): CD006201. |
[38] | Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda[J]. PLoS Clin Trials, 2006, 1(8): e39. |
[39] | Franco JR, Simarro PP, Diarra A, et al. Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis[J]. Res Rep Trop Med, 2012, 3: 93-101. |
[40] | Schmid C, Kuemmerle A, Blum J, et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness[J]. PLoS Negl Trop Dis, 2012, 6(11): e1920. |
[41] | Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study[J]. BMJ, 2008, 336(7646): 705-708. |
[42] | Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis[J]. Clin Infect Dis, 2005, 41(5): 748-751. |
[43] | Schmid C, Richer M, Bilenge CM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment oflate-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II)[J]. J Infect Dis, 2005, 191(11): 1922-1931. |
[44] | Reto B, Johannes B, Francois C, et al. Human African trypanosomiasis[J]. Handb Clin Neurol, 2010, 114: 169-181. |
[45] | Kibona SN, Matemba L, Kaboya JS, et al. Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania[J]. Trop Med Int Health, 2006, 11(2): 144-155. |
[46] | Pyana PP, Sere M, Kaboré J, et al. Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo[J]. Infect Genet Evol, 2015, 30: 128-133. |
[47] | Baker N, de Koning HP, M ser P, et al. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story[J]. Trends Parasitol, 2013, 29(3): 110-118. |
[48] | Simarro PP, Diarra A, Ruiz Postigo JA, et al. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward[J]. PLoS Negl Trop Dis, 2011, 5(2): e1007. |
[49] | Balasegaram M, Harris S, Checchi F, et al. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo[J]. Bull World Health Organ, 2006, 84(10): 783-791. |
[50] | Robays J, Nyamowala G, Sese C, et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo[J]. Emerging Infect Dis, 2008, 14(6): 966-967. |
[51] | 杜金, 朱明彦. 人类非洲锥虫病的治疗研究进展[J]. 现代生物医学进展, 2015, 15(6): 1154-1159. |
[52] | Field MC, Horn D, Fairlamb AH, et al. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need[J]. Nat Rev Microbiol, 2017, 15(7): 447. |
[53] | Patrick DA, Gillespie JR, McQueen J, et al. Urea derivatives of 2-Aryl-benzothiazol-5-amines: a new class of potential drugs for human African trypanosomiasis[J]. J Med Chem, 2017, 60(3): 957-971. |
[54] | Tarral A, Blesson S, Mordt OV, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies[J]. Clin Pharmacokinet, 2014, 53(6): 565-580. |
[55] | Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis[J]. PLoS Negl Trop Dis, 2011, 5(6): e1151. |
[56] | Carrillo AK, Guiguemde WA, Guy RK.Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT)[J]. Bioorg Med Chem, 2015,23(16): 5151-5155. |
[57] | Priotto G, Chappuis F, Bastard M, et al. Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis[J]. PLoS Negl Trop Dis, 2012, 6(6): e1662. |
[58] | Lejon V, Buscher P.Stage determination and follow-up in sleeping sickness[J]. Med Trop (Mars), 2001, 61(4/5): 355-360. |
[59] | Lejon V, Büscher P.Review article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up[J]. Trop Med Int Health, 2005, 10(5): 395-403. |
[60] | Mumba Ngoyi D, Lejon V, Pyana P, et al. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness[J]. J Infect Dis, 2010, 201(3): 453-463. |
[61] | Liu Q, Chen XL, Chen MX, et al. Trypanosoma brucei rhodesiense infection in a Chinese traveler returning from the Serengeti National Park in Tanzania[J]. Infect Dis Poverty, 2018, 7(1): 50. |
[1] | 王登辉, 张艳, 聂蔷, 刘红威. 结肠小袋纤毛虫感染1例[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(5): 647-649. |
[2] | 蔡长煌, 张芝平, 卓鸣莺, 郭理平, 傅志辉, 刘亦若. 基于虫卵内转录间隔区2序列分析诊断麝猫后睾吸虫和华支睾吸虫感染[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(4): 427-433. |
[3] | 张旭, 孙希萌. 旋毛虫感染免疫逃逸机制研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(4): 492-496. |
[4] | 曹伟, 王一, 张熙致, 仝国栋, 杨超, 沈燕, 赵亚. 脑型疟辅助治疗研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(3): 361-373. |
[5] | 肖长林, 杨柳柳, 方勇, 冯浠镰. 肺粪类圆线虫合并豚鼠耳炎诺卡菌感染1例[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(6): 810-812. |
[6] | 陈睿, 袁琼辉, 夏万宝. 1例罕见原发性阿米巴脑膜脑炎病例的实验室诊断[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 616-621. |
[7] | 秦敏, 王立英. 阿苯达唑联合药物治疗棘球蚴病的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 647-655. |
[8] | 刘继兵, 赵洪喜. 基于18S rRNA的胎毛滴虫感染PCR诊断方法的建立[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 682-685. |
[9] | 国家传染病医学中心撰写组. 疟疾诊疗指南[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 419-427. |
[10] | 曹磊, 马琳, 朱妮, 张义, 王安礼, 王舒, 李欣欣. 2011—2020年陕西省疟疾流行特征[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 454-459. |
[11] | 乔飞, 刘鏊, 余复昌, 齐萌. 1例牛带绦虫感染的诊断和鉴定[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(3): 285-287. |
[12] | 赵紫琪, 吕芳丽. 免疫功能健全者获得性弓形虫病的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(2): 228-235. |
[13] | 蔡子涵, 曹颖, 朱逢龙, 李倩, 和艳红, 杨毅梅. 纳米金棒标记技术应用于旋毛虫感染诊断的研究[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(5): 652-658. |
[14] | 张耀光, 江莉, 王真瑜, 朱民, 朱倩, 马晓疆, 吴寰宇. 上海市2例输入性卵形疟误诊病例的实验室诊断分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(4): 553-556. |
[15] | 黄子芸, 吕芳丽. 实体器官移植与弓形虫病[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 386-392. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||